News

Cellenkos, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Treatment-Resistant Guillain-Barré Syndrome

October 16th 2018

HOUSTON, Oct. 16, 2018 /PRNewswire/ -- Cellenkos, a clinical-stage biotechnology company, announced that the United States Food and Drug Administration has cleared its Investigational New Drug (IND) application to proceed with a phase I clinical trial of CK0801, allogeneic cord blood-derived regulatory T cells, in patients with treatment-resistant Guillain-Barré Syndrome (GBS). Cellenkos submitted its IND application on September 11, 2018 and received approval on October 11, 2018.


https://www.prnewswire.com/news-releases/cellenkos-inc-announces-fda-clearance-of-investigational-new-drug-application-for-ck0801-for-treatment-resistant-guillain-barre-syndrome-300731539.html



Cellenkos, Inc. Announces Neuroinflammation Research Collaboration with The University of Texas Health Science Center at Houston

June 22nd 2018

HOUSTON, June 22, 2018 /PRNewswire/ -- Cellenkos™ and The University Of Texas Health Science Center at Houston today announce a research collaboration for application of cord blood-derived regulatory T cells (CK0801) as adoptive therapy for treatment of neuroinflammatory disorders. The first condition to be studied will include Guillain-Barré Syndrome (GBS), a rare disorder in which the body's immune system attacks part of the peripheral nervous system. Patients with GBS who have not responded to standard therapies will be evaluated for CK0801 therapy.


https://www.prnewswire.com/news-releases/cellenkos-inc-announces-neuroinflammation-research-collaboration-with-the-university-of-texas-health-science-center-at-houston-300671145.html



Cellenkos™, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Bone Marrow Failure Syndromes

June 10th 2018

HOUSTON, June 10, 2018 /PRNewswire/ -- Cellenkos™, Inc., a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration has cleared the Investigational New Drug (IND) application which allows for Cellenkos™ to proceed with a phase I clinical trial of CK0801, 3rd party cord blood derived regulatory T cells, in patients with bone marrow failure syndrome including aplastic anemia, myelodysplastic syndrome and myelofibrosis.  Cellenkos™ submitted its IND application on May 11, 2018.  The Phase I clinical trial of CK0801 will commence in the third quarter of 2018 at The University of Texas MD Anderson Cancer Center, Houston, Texas.

https://www.prnewswire.com/news-releases/cellenkos-inc-announces-fda-clearance-of-investigational-new-drug-application-for-ck0801-for-bone-marrow-failure-syndromes-300663808.html



Cellenkos, Inc. Announces Alick Sun as Senior Vice President for Corporate and Business Development

April 13th 2018

HOUSTON, April 13, 2018 /PRNewswire/ -- Today, Cellenkos Inc. announced the appointment of Alick Sun as Senior Vice President for Corporate & Business Development, further strengthening its executive team as the company continues reinforcing the foundation for long-term growth. He will be responsible for leading all business and corporate development activities. Alick Sun is the senior VP of Golden Meditech Holdings Limited, and holds a concurrent position in Cellenkos. Golden Meditech is an integrated healthcare group in China and a major shareholder of Cellenkos.

https://www.prnewswire.com/news-releases/cellenkos-inc-announces-alick-sun-as-senior-vice-president-for-corporate-and-business-development-300629354.html



Cellenkos, Inc. Announces FDA Registration of GMP Manufacturing Facility

February 6th 2018

HOUSTON, Feb. 6, 2018 /PRNewswire/ -- Cellenkos, Inc., a clinical-stage biotechnology company focused on developing universal donor cell therapeutics derived from cord blood (CB) for the treatment of autoimmune diseases and inflammatory conditions, today announced the successful registration of its stand-alone, manufacturing facility as GMP (good manufacturing practice) compliant with U.S. Food and Drug Administration (FDA).

https://www.prnewswire.com/news-releases/cellenkos-inc-announces-fda-registration-of-gmp-manufacturing-facility-300593842.html



Cellenkos Inc. Appoints Tara Sadeghi as Senior Director of Clinical Operations

December 1st 2017

HOUSTON, Dec. 1, 2017 /PRNewswire/ -- Cellenkos Inc., an early stage clinical biotechnology company developing umbilical cord blood derived T-regulatory (Treg) cellular therapies for the treatment of autoimmune diseases and inflammatory disorders, announced today that Tara Sadeghi was appointed as Senior Director of Clinical Operations. Ms. Sadeghi joins Cellenkos, where she will provide senior oversight to clinical operations and ensure quality execution of all projects.  “We are excited to have an experienced management team to which Tara Sadeghi brings over 25 years of clinical research experience, leadership and impeccable attention to detail.  Her warmth of character and level of professionalism make her an outstanding fit with the Cellenkos family,” said Cellenkos Chief Medical Officer, Simrit Parmar, MD. 

https://www.prnewswire.com/news-releases/cellenkos-inc-appoints-tara-sadeghi-as-senior-director-of-clinical-operations-300564795.html



Cellenkos Inc. Enters Regulatory T-Cell Platform Research Collaboration with MD Anderson

November 15th 2017

Houston, TX, November 15, 2017 -- Cellenkos Inc. has announced a multi-year collaboration with The University of Texas MD Anderson Cancer Center focused on development of cord blood regulatory T cell (CB TREG) therapeutics for treatment of autoimmune disease and inflammatory disorders. As part of this collaboration, Cellenkos Inc. will fund up to 10,000,000 USD over the next 5 years to establish and support the TREG Program at MD Anderson. This program will be led by Dr. Simrit Parmar, Chief, Section of Autoimmune Diseases and Inflammatory Disorders and Dr. Varsha Gandhi, Chair, Department of Experimental Therapeutics.

https://www.pr.com/press-release/735991





Golden Meditech and MD Anderson Team Up to Create Cellenkos, Inc.

September 18th 2016

HONG KONG and HOUSTON, Sept. 18, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a Hong Kong-based integrated healthcare enterprise, and The University of Texas at MD Anderson Cancer Center ("MD Anderson") have announced the creation of Cellenkos, Inc. ("Cellenkos"), a start-up enterprise focused on umbilical cord blood derived T-regulatory ("T-reg") cellular therapies.

http://www.prnewswire.com/news-releases/golden-meditech-and-md-anderson-team-up-to-create-cellenkos-inc-300329880.html